S.Amdt. 33

SA 33. Ms. KLOBUCHAR (for herself, Ms. Hassan, and Mr. Van Hollen)
submitted an amendment intended to be proposed by her to the concurrent
resolution S. Con. Res. 3, setting forth the congressional budget for
the United States Government for fiscal year 2017 and setting forth the
appropriate budgetary levels for fiscal years 2018 through 2026; which
was ordered to lie on the table; as follows:

At the end of title III, add the following:

SEC. 3___. DEFICIT-NEUTRAL RESERVE FUND RELATING TO
PRESCRIPTION DRUGS.

The Chairman of the Committee on the Budget of the Senate
may revise the allocations of a committee or committees,
aggregates, and other appropriate levels in this resolution
for one or more bills, joint resolutions, amendments,
amendments between the Houses, motions, or conference reports
relating to eliminating anticompetitive pay-for-delay patent
settlements between branded drug and generic drug
manufacturers that delay competition and increase
prescription drug costs by the amounts provided in such
legislation for those purposes, provided that such
legislation would not increase the deficit over either the
period of the total of fiscal years 2017 through 2021 or the
period of the total of fiscal years 2017 through 2026.
______